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The aim of this paper was to assess serum uric acid (SUA) levels in patients with type 2 diabetes mellitus (T2DM) with or without
sudomotor dysfunction (evaluated by the Neuropad test). We included 36 T2DM patients with sudomotor dysfunction (group
A: mean age 63.1 ± 2.6 years) and 40 age-, gender-, renal function- and T2DM duration-matched patients without sudomotor
dysfunction (group B: mean age 62.1 ± 3.1 years). SUA was signiﬁcantly higher in group A (P<0.001). There was a signiﬁcant
correlationbetween SUA andNeuropadtimetocolour change inbothgroups (groupA: rs = 0.819, P<0.001;groupB:rs = 0.774,
P<0.001). There was also a signiﬁcant positive correlation between SUA and CRP in both groups (group A: rs = 0.947, P<0.001;
group B: rs = 0.848, P<0.001). In conclusion, SUA levels were higher in T2DM patients with sudomotor dysfunction than those
without this complication. The potential role of SUA in sudomotor dysfunction merits further study.
1.Introduction
Diabetic autonomic neuropathy (DAN) is a major cause
of morbidity and mortality [1, 2]. A rather neglected
manifestationofDANisimpairedsweatsecretion,alsocalled
sudomotor dysfunction [3]. This is due to injury of the
postganglionic cholinergic sympathetic nerve ﬁbres which
areresponsiblefortheinnervationofsweatglandsandcauses
dry skin [3].
Serum uric acid (SUA) is being considered as a risk mar-
ker of cardiovascular morbidity [4–9]. Elevated SUA levels
are associated with endothelial dysfunction [10], coronary
artery disease [4–6], stroke [11, 12], peripheral arterial dise-
ase (PAD) [13, 14], as well as cardiovascular mortality [5, 7].
Furthermore, a link between increased SUA levels and
nonalcoholic fatty liver disease (NAFLD) has been reported
[15]. Speciﬁcally, in patients with type 2 diabetes mellitus
(T2DM), high SUA levels have been linked with macrovas-
cular disease [16], namely, stroke [17]a n dP A D[ 18] while
the association between SUA and microvascular disease has
received little attention. More recently, however, some data
on its relationship with microangiopathy have become avail-
able.Indeed,patientswithT2DMandperipheralneuropathy
have been reported to have higher SUA [19]. There was also
an association between SUA levels and clinical severity of
neuropathy [19].
Despite the reported association between SUA levels and
peripheral neuropathy, the potential association with DAN
has not been examined. The rationale for this association is
that SUA reﬂects inﬂammatory activity [9, 10], and patients
with DAN may exhibit increased inﬂammation [20]. In
particular, SUA levels have not been examined in diabetic
patients with sudomotor dysfunction. Of note, there is
evidence linking SUA levels and the amount of sweating,
at least in healthy volunteers [21]; however, the eﬀect of
sudomotor dysfunction on this relationship is unclear. Thus,
we examined the association between SUA and sudomotor
dysfunction in patients with T2DM. It is also of interest that
both SUA [5, 7]a n dD A N[ 1, 2] may predict cardiovascular
mortality.2 Experimental Diabetes Research
Table 1: Characteristics of patients with (group A) versus without
(group B) sudomotor dysfunction.
Characteristic Group A
(n = 36)
Group B
(n = 40) P
Men (n,% ) 17
(47.2%)
19
(47.5%) 0.981
Age (years, mean
± SD) 63.1±2.66 2 .1±3.1 0.251
Serum creatinine
(mg/dL, mean ±
SD)
0.9 ±0.10 .8 ±0.1 0.322
eGFR (mL/min,
mean ± SD) 85 ±58 6 ±5 0.508
Diabetes duration
(years, mean ±
SD)
9.4 ±2.18 .9 ±1.9 0.246
HbA1c (%, mean
± SD) 7.7 ±0.47 .6 ±0.5 0.750
BMI (kg/m2,
mean ± SD) 31.5±1.83 2 .1±1.8 0.210
Smoking (n,% ) 13
(36.1%)
13
(32.5%) 0.929
Hypertension (n,
%) 27 (75%) 31
(77.5%) 0.999
CAD (n,% ) 12
(33.3%)
13
(32.5%) 0.999
Retinopathy (n,
%) 18 (50%) 24 (60%) 0.519
Microalbuminuria
(n,% )
16
(44.4%) 12 (30%) 0.287
2. Patientsand Methods
The present study included 36 T2DM patients with sudo-
motor dysfunction (group A) and 40 T2DM patients with-
out sudomotor dysfunction (group B). These groups were
matched for age, gender, renal function (assessed by serum
creatinine), and diabetes duration. Patient characteristics
are presented in Table 1.S u b j e c t sw e r er e c r u i t e df r o mt h e
Outpatient Clinic of Obesity, Diabetes and Metabolism,
Second Department of Internal Medicine at Democritus
University of Thrace, Greece. The study was carried out in
accordance with the Helsinki Declaration of Human Rights
and patients gave their informed consent.
Exclusion criteria were age <17 or >75 years, chronic
renal failure, PAD, stroke, other potential causes of neuropa-
thy (i.e., alcohol abuse, vitamin B12 deﬁciency, peripheral
nerve lesions, or malignancy), acute or chronic infections
o ri n ﬂ a m m a t i o n ,h a e m a t o l o g i c a ld i s e a s e ,a sw e l la su s e
of statins, anti-inﬂammatory agents, antibiotics, or any
medication that might inﬂuence SUA levels (e.g., diuretics,
cyclosporin, allopurinol, oestrogens, or cytotoxic agents)
[22–24] during the previous 3 months.
Sudomotor dysfunction was diagnosed by means of the
indicator test Neuropad (Trigocare International GmbH,
Wiehl, Germany) [25]. This is a relatively new test, which
assesses sweat production by means of a chemical reaction
between water and anhydrous cobalt dichloride [25, 26]. The
test is applied to an area free from callus and hyperkeratosis
on the plantar aspect of the foot between the ﬁrst and second
metatarsal head [25]. In case of adequate sweat production,
the test changes its colour from blue to pink within 600sec.
If such colour change does not occur within this time frame,
sudomotor dysfunction is diagnosed. The severity of the
latter can be evaluated by measuring the absolute time to
colourchange[25,26].Inthepresentstudy,the600seccutoﬀ
was used to diagnose sudomotor dysfunction while time to
colour change was measured to evaluate its severity [25].
SUA,serumcreatinine,C-reactiveprotein(CRP),triglyc-
erides (TGs), total cholesterol (TC), high-density lipoprotein
cholesterol (HDL-C), and low-density lipoprotein choles-
terol (LDL-C) were measured by spectrophotometry (Olym-
pus AU 2700 autoanalyzer, Hamburg, Germany). Glomeru-
larﬁltrationrate(GFR)wascalculatedbytheCockroft-Gault
formula. Haemoglobin A1c (HbA1c) was assessed by high-
performanceliquidchromatography(G7HPLCGlycohemo-
globin Analyzer, Tosoh Bioscience, Inc., South San Franci-
sco, CA, USA). Urinary albumin was measured by an immu-
nonephelometric method (Immage 800, Beckman-Coulter,
Inc., Brea, CA, USA).
Smoking was deﬁned as daily consumption of ≥1
cigarette for at least 2 years during the preceding 5 years.
In accordance with the seventh report of the Joint National
Committee on prevention, detection, evaluation, and treat-
ment of high blood pressure (JNC7), we deﬁned arterial
hypertension as a systolic blood pressure ≥140mmHg
and/or diastolic blood pressure ≥90mmHg on 3 separate
occasions [27] or as antihypertensive treatment. Coronary
artery disease (CAD) was diagnosed on the basis of history
of myocardial infarction and/or electrocardiographic ﬁnd-
ings [28]. Microalbuminuria was diagnosed when albumin
excretion rate was ≥20µg/min in the absence of uncon-
trolled hypertension and/or urinary tract infection [29]a n d
recorded as present or absent. Retinopathy was deﬁned as at
least 2 microaneurysms and/or retinal haemorrhage and/or
other signs of retinal damage [30]. Body mass index (BMI)
was calculated by dividing subjects’ weight by their squared
height (kg/m2).
Statistical analysis was performed using the SPSS (Sta-
tistical Package for Social Sciences, Chicago, Illinois) version
13.0. Normally distributed quantitative variables were anal-
ysed by unpaired t-test. Qualitative variables were compared
by chi-square (after Yates’ correction when appropriate).
Correlations between Neuropad time to colour change
and/or biochemical variables (i.e., SUA, TG, TC, HDL-C,
LDL-C, serum creatinine, GFR, and CRP) were evaluated by
Spearman’s coeﬃcient (rs). Data were expressed as mean ±
standard deviation (SD). A 2-tailed P ≤ 0.05 was considered
signiﬁcant.
3. Results
There were no diﬀerences between the 2 groups in demogra-
phic characteristics, glycaemic control (assessed by HbA1c),
renal function (assessed by serum creatinine and GFR), and
frequency of diabetic complications other than neuropathyExperimental Diabetes Research 3
(Table 1). SUA levels were signiﬁcantly higher in group A
versus B (8.2 ± 1.4v e r s u s5 .8 ± 1.1mg/dL,P<0.001). The
same was observed for CRP (1.0±0.4v e r s u s0 .3±0.2mg/dL,
P<0.001) and TGs (158 ± 24 versus 146 ± 17mg/dL,
P = 0.016), but not for TC (177±19 versus 175±18mg/dL,
P = 0.83),LDL-C(102±19versus102±20mg/dL,P = 0.98),
and HDL-C (43 ±7v e r s u s4 4±6mg/dL,P = 0.38).
Overall, there was a signiﬁcant positive correlation bet-
ween SUA and Neuropad time to colour change (rs = 0.874,
P<0.001). This correlation was observed both in group A
(rs = 0.819, P<0.001) and in group B (rs = 0.774, P<
0.001). Furthermore, there was a signiﬁcant positive correla-
tion between SUA and CRP (rs = 0.935, P<0.001), which
was also observed both in group A (rs = 0.947, P<0.001)
and in group B (rs = 0.848, P<0.001).
A signiﬁcant correlation between SUA and TGs was
observed in group A (rs = 0.556, P<0.001) but not in group
B( rs = 0.185, P = 0.254). Moreover, there was a signiﬁcant
negative correlation between SUA and HDL-C in group A
(rs =− 0.400, P = 0.016) but not in group B (rs = 0.291, P =
0.130). SUA did not correlate with TC (group A: rs = 0.285,
P = 0.920; group B: rs = 0.156, P = 0.335) or LDL-C (group
A: rs = 0.321, P = 0.610; group B: rs = 0.290, P = 0.710).
There was no correlation between SUA and HbA1c in either
group(groupA:rs =− 0.072,P = 0.676;groupB:rs = 0.182,
P = 0.260).
Overall, there was a signiﬁcant positive correlation bet-
weenSUAandserumcreatinine(rs = 0.428,P = 0.001).This
correlation was observed both in group A (rs = 0.580, P =
0.001) and in group B (rs = 0.370, P = 0.029). SUA also cor-
related negatively with GFR (rs =− 0.510, P = 0.001). This
correlation was observed both in group A (rs =− 0.601,
P = 0.002) and in group B (rs =− 0.410, P = 0.004).
4. Discussion
Our main ﬁnding is that SUA levels are increased in the
presence of sudomotor dysfunction among patients with
T2DM. Of note, the 2 groups were matched for renal
function (assessed by serum creatinine and GFR), as well
as age, diabetes duration, and HbA1c. These novel ﬁndings
extend our previous observation of elevated SUA in patients
with peripheral diabetic neuropathy [19]. Hence, it appears
that the association between SUA and diabetes-related
neuropathy exists both for peripheral neuropathy and for
sudomotor dysfunction. Importantly, there was a signiﬁcant
positive correlation between SUA and Neuropad time to
colour change, a marker of the severity of sudomotor
dysfunction [26]. This correlation was observed in both
groups, as well as among the entire patient population,
suggesting a continuum of increasing SUA levels with
progression of sudomotor dysfunction.
Moreover, patients with sudomotor dysfunction exhib-
ited signiﬁcantly higher CRP levels than those without
sudomotor dysfunction. There was a signiﬁcant positive
correlation between CRP and SUA levels in both groups
and in the entire patient population. An association between
neuropathyandCRPhasbeenreportedbyus[19]andothers
[21, 31]. The role of inﬂammation in diabetic neuropathy
has also become apparent by the observation of elevated
interleukin-6 levels in the presence of this complication
[31, 32]. Our results provide further support for the role of
inﬂammation in neuropathy, as well as the ﬁrst suggestion
that inﬂammation is important in the context of sudomotor
dysfunction. As SUA has been shown to exert antioxidant
properties [33, 34], it is possible that inﬂammatory activity
may induce an elevation of SUA levels.
Another ﬁnding was the association of sudomotor dys-
function with increased TGs and reduced HDL-C. We have
previously shown that peripheral neuropathy is associated
with increased TGs and TC, but not HDL-C, in T2DM
[19]. Despite some minor diﬀerences in the lipid fractions
involved, these ﬁndings highlight the importance of dyslipi-
daemia in diabetic neuropathy. Our results are in agreement
with experimental evidence that elevated TG and oxidised
LDL are neurotoxic via oxidative stress, independently of
hyperglycaemia [35]. Others have also implicated hyper-
lipidaemia in diabetic neuropathy and identiﬁed elevated
serum lipids as a potential additional therapeutic target in
themanagementofthismicrovascularcomplication[36–38].
These observations may explain why SUA correlated with
dyslipidaemia but not with HbA1c.
The limitations of the study include that it was not
prospective, and thus the potential role of SUA in the devel-
opment of sudomotor dysfunction could not be examined.
Secondly, we assessed a relatively small number of patients
and they were recruited in a specialist unit. Therefore,
caution is needed before applying our results to the general
T2DM population. Furthermore, Neuropad has not yet
been established as the gold standard for the assessment of
sudomotor dysfunction. However, the more sophisticated
modalities, such as the quantitative sudomotor axon reﬂex
test, are only available in a handful of specialised centres
acrosstheworldandarefartoocumbersometouseinclinical
practice [3]. Neuropad is the only widely available test for
broad assessment of sudomotor dysfunction and dry foot
[26].Ofnote,theliteratureontheapplicationofNeuropadis
everincreasing[38–40],lendingfurthersupporttoitsusefor
the evaluation of this manifestation of neuropathy. Finally,
no information on nutritional habits was available, and so
the potential contribution of dietary factors could not be
accurately evaluated. However, all patients received dietary
advice as part of their routine care.
Our results may have the following practical implica-
tions. T2DM patients with sudomotor dysfunction exhibit
signiﬁcantly higher SUA than those without. SUA levels
are elevated in association with the severity of sudomotor
dysfunction and they are associated with increased CRP and
dyslipidaemia. Based on these ﬁndings, SUA may be consid-
ered a potentially useful additional marker for sudomotor
dysfunction. This role should be discussed in the context of
the emerging evidence for the contribution of inﬂammation
[19, 21, 31, 32], hyperlipidaemia [19, 35–37, 41], and other
factors to the pathogenesis of diabetes-related neuropathy,
highlighting the necessity for multifactorial intervention [42,
43]. Nonetheless, 3 important issues remain to be clariﬁed.
First,theputativecontributionofSUAtothedevelopmentof
sudomotor dysfunction needs to be examined in long-term4 Experimental Diabetes Research
prospective studies. Secondly, we need to investigate whether
SUA is elevated in patients with other manifestations of
DAN, notably reduced heart rate variability or gastroparesis.
Finally,itremainstobeestablishedwhetherpharmacological
reduction of SUA might contribute to the management
and/or prevention of sudomotor dysfunction, as may be
possible for cardiovascular disease [9, 11, 33] and metabolic
syndrome [44].
In conclusion, SUA levels are higher in T2DM patients
with sudomotor dysfunction compared with those without
this complication. A signiﬁcant positive correlation was
observed between SUA and the severity of sudomotor
dysfunction. Furthermore, SUA levels are associated with
CRP. In subjects with sudomotor dysfunction, SUA also
correlates with an adverse lipid proﬁle. The present ﬁndings
suggest that prospective studies should further examine
the contribution of SUA to the development of sudomotor
dysfunction.
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